Alicia Irurzun-Lafitte

Alicia Irurzun-Lafitte joined UCB Ventures in 2019 as Partner. Alicia joined from M Ventures, the corporate venture arm of Merck KGaA where she was instrumental in the closing of multiple investments in Oncology, Immunology and Fertility areas in the US and Europe. She was also closely involved with the built-up of spin-offs. Prior to ventures, Alicia held roles in global business development at Merck Serono in Geneva and EMD Serono in Boston. During her time in business development she closed multiple transactions and was involved in strategic corporate development initiatives. She currently serves on the Boards of Walden Biosciences, Switch Therapeutics and Farnia Biosciences.  She is an Observer on the Board of CodeBio. Alicia holds a MSc from Leiden University in Biopharmaceutical Sciences and an MBA from Babson College. Alicia lives in New Jersey with her husband and two sons. She loves travelling, cooking and practicing yoga.